<p>默克公司正在积极重建其制药实力，这一次它在人工智能上下注数十亿美元。该公司与 Valo Health 签署了一项新合作协议，价值可能超过 30 亿美元，使默克能够访问一个基于超过 1700 万患者记录和生物样本训练的人工智能平台。目标既简单又雄心勃勃：识别帕金森病及相关疾病的病理模式和潜在靶点，此时默克可能希望在经历了两次管线挫折和对一些老产品的竞争压力增加后重新获得动力。</p>
<p>对于 Valo 来说，这笔交易为其已经包括诺和诺德在内的合作伙伴名单增添了另一个重量级名字，进一步证明其基于人工智能的方法可能在行业内获得了关注。周四宣布的协议包括预付款、潜在里程碑、版税和研发资金，尽管公司并未详细说明财务细节。虽然 Valo 继续推进其自身的实验项目，但像这样的合作可能是该公司更快扩展其平台的一种方式。</p>
<p>这一最新举措恰逢首席执行官贝伦·加里霍（Belen Garijo）准备在 5 月辞职，此前她推动了一系列旨在加强默克管线的交易。最近收购的 SpringWorks Therapeutics 已经开始为销售做出贡献，而与 Skyhawk Therapeutics 在 8 月达成的协议则针对高未满足需求的神经系统疾病。随着默克的关键多发性硬化症增长驱动剂 Mavenclad 面临美国专利失利后可能出现的早于预期的仿制药竞争，这一新的人工智能合作伙伴关系可能是默克在神经学领域重建动力的长期战略的重要组成部分。</p>

德国默克

默克

<p>德国默克与 Valo Health 合作，启动一项价值 30 亿美元的人工智能驱动计划，以识别帕金森病的疾病模式。这一战略举措旨在重建默克的制药管道，以应对竞争压力和管道挫折。该合作包括预付款、里程碑付款、版税和研发资金。首席执行官贝伦·加里霍即将离职以及最近的收购，突显了默克加强其神经学管道的重点</p>

<p>Merck KGaA  is making a fresh push to rebuild its pharmaceutical firepower, and this time it is placing a multibillion-dollar bet on artificial intelligence. The company has signed a new partnership with Valo Health that could be worth more than $3 billion, handing Merck access to an AI platform trained on over 17 million patient records and biobank samples. The goal is straightforward but ambitious: identify disease patterns and potential targets for Parkinson's and related disorders at a moment when Merck could be looking to regain momentum after two pipeline setbacks and increasing competitive pressure on some older products.</p>
<div class="lb-trans"><p>默克公司正在积极重建其制药实力，这一次它在人工智能上下注数十亿美元。该公司与 Valo Health 签署了一项新合作协议，价值可能超过 30 亿美元，使默克能够访问一个基于超过 1700 万患者记录和生物样本训练的人工智能平台。目标既简单又雄心勃勃：识别帕金森病及相关疾病的病理模式和潜在靶点，此时默克可能希望在经历了两次管线挫折和对一些老产品的竞争压力增加后重新获得动力。</p>
</div><p>For Valo, the deal adds another heavyweight name to a partnership list that already includes Novo Nordisk, reinforcing how its AI-driven approach might be gaining traction across the industry. The agreement announced Thursday bundles upfront payments, potential milestones, royalties, and R&amp;D funding, though the companies did not break down the financials. While Valo continues to advance its own experimental programs, collaborations like this could be a way for the company to scale its platform more quickly.</p>
<div class="lb-trans"><p>对于 Valo 来说，这笔交易为其已经包括诺和诺德在内的合作伙伴名单增添了另一个重量级名字，进一步证明其基于人工智能的方法可能在行业内获得了关注。周四宣布的协议包括预付款、潜在里程碑、版税和研发资金，尽管公司并未详细说明财务细节。虽然 Valo 继续推进其自身的实验项目，但像这样的合作可能是该公司更快扩展其平台的一种方式。</p>
</div><p>This latest move also lands as CEO Belen Garijo prepares to step down in May, after pushing through a sequence of transactions aimed at strengthening Merck's pipeline. The recently acquired SpringWorks Therapeutics has already begun contributing to sales, and an August agreement with Skyhawk Therapeutics is targeting neurological conditions with high unmet need. With Mavenclad, one of Merck's key multiple sclerosis growth drivers, now facing the possibility of earlier-than-expected generic competition following a US patent blow, this new AI-enabled partnership could be an important piece of Merck's longer-term strategy to rebuild momentum in neurology.</p>
<div class="lb-trans"><p>这一最新举措恰逢首席执行官贝伦·加里霍（Belen Garijo）准备在 5 月辞职，此前她推动了一系列旨在加强默克管线的交易。最近收购的 SpringWorks Therapeutics 已经开始为销售做出贡献，而与 Skyhawk Therapeutics 在 8 月达成的协议则针对高未满足需求的神经系统疾病。随着默克的关键多发性硬化症增长驱动剂 Mavenclad 面临美国专利失利后可能出现的早于预期的仿制药竞争，这一新的人工智能合作伙伴关系可能是默克在神经学领域重建动力的长期战略的重要组成部分。</p>
</div>

默克 30 亿美元的 AI 赌注：深入了解破解帕金森病的大胆尝试